Anemia Defisiensi B9 (Asam Folat)

01Pathophysiology

Folic acid (vitamin B9) serves as an essential cofactor in one-carbon transfer reactions, most critically in the synthesis of thymidylate, which is a building block of DNA. Without adequate folate, the enzyme thymidylate synthase cannot convert deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). This disruption stalls DNA replication while RNA and protein synthesis continue unimpaired. The result is a cell that grows in cytoplasmic volume but cannot divide its nucleus properly, producing the characteristic megaloblastic change: large, immature erythroid precursors in the bone marrow and macrocytes in the peripheral blood.

The cells most vulnerable to this defect are those with the highest turnover rates. Bone marrow hematopoietic precursors are affected first, leading to anemia, but gastrointestinal epithelial cells are also impaired, which explains the glossitis and diarrhea that may accompany this condition.

Folate is absorbed primarily in the jejunum. Unlike vitamin B12, which has body stores lasting 3 to 5 years, folate stores are limited and can be depleted within 3 to 4 months of inadequate intake. This is why folate deficiency develops much faster than B12 deficiency when dietary intake drops, and why it is the more common cause of megaloblastic anemia in settings of malnutrition and chronic alcohol use.

Folate also participates alongside vitamin B12 in the conversion of homocysteine to methionine. When folate is deficient, homocysteine accumulates, leading to elevated serum homocysteine levels. However, folate plays no role in the conversion of methylmalonyl-CoA to succinyl-CoA, a reaction that depends exclusively on vitamin B12. This biochemical distinction is the reason methylmalonic acid remains normal in isolated folate deficiency but is elevated in B12 deficiency. This single lab finding is one of the highest-yield discriminators on any exam.

The reason folate deficiency does not produce neurological symptoms lies in this same biochemistry. The demyelination seen in B12 deficiency results from impaired methylmalonyl-CoA metabolism and subsequent accumulation of abnormal fatty acids incorporated into myelin. Since folate does not participate in that pathway, the nervous system is spared in pure folate deficiency.

02Classification and Clinical Manifestation

Folic acid deficiency does not follow a formal staging classification in the same way some diseases do, but the clinical manifestations can be organized by the timeline of depletion and the organ system affected.

Unlike vitamin B12 deficiency, there are no neurological findings such as subacute combined degeneration, peripheral neuropathy, loss of vibration or position sense, or ataxia. If a vignette describes megaloblastic anemia with neurological deficits, that points toward B12 deficiency, not folate.

03Diagnostic Workup

The workup begins when a patient presents with fatigue and a CBC reveals macrocytic anemia with an MCV exceeding 100 fL. The next step is to review the peripheral blood smear. The hallmark finding is the hypersegmented neutrophil, which is essentially pathognomonic for megaloblastic anemia (either folate or B12 deficiency). You may also see macro-ovalocytes and occasional Howell-Jolly bodies.

Once megaloblastic anemia is identified on smear, the critical diagnostic question becomes: is this folate deficiency, B12 deficiency, or both? The best initial tests to order are serum folate and serum vitamin B12 levels simultaneously. Serum folate below 3 ng/mL supports the diagnosis, though this value can fluctuate based on recent meals. If there is clinical suspicion but serum folate is borderline, RBC folate is the more reliable marker because it reflects folate status over the lifespan of the red blood cell (approximately 120 days).

To definitively distinguish folate from B12 deficiency when levels are ambiguous, order both homocysteine and methylmalonic acid. The diagnostic pattern is:

This distinction is the single most tested laboratory concept in this topic. A normal MMA with elevated homocysteine points to folate deficiency. An elevated MMA with elevated homocysteine points to B12 deficiency. Both elevated with a low B12 and low folate suggests combined deficiency.

A bone marrow biopsy is not routinely needed but would show megaloblastic erythroid hyperplasia with large erythroid precursors if performed. This is rarely the tested next step.

04Management and Treatment

The treatment of folic acid deficiency is straightforward, but there is one critical rule that is tested repeatedly: you must exclude vitamin B12 deficiency before initiating folic acid replacement alone. Folate supplementation will correct the hematologic abnormalities (the anemia will improve, the MCV will normalize, hypersegmented neutrophils will disappear), but it will not correct the neurological damage caused by B12 deficiency. Worse, by correcting the blood picture, folate supplementation removes the clinical warning sign that would prompt investigation for B12 deficiency, allowing subacute combined degeneration of the spinal cord to progress silently and irreversibly. Exam vignettes love to test this concept.

Once B12 deficiency is excluded, treatment is oral folic acid at 1 to 5 mg per day. Response is rapid. You should see a rise in reticulocyte count within 5 to 7 days (the reticulocyte peak), and hemoglobin should normalize over 1 to 2 months. Treatment is continued for 1 to 4 months or until the underlying cause is corrected.

For patients whose folate deficiency is caused by methotrexate or another dihydrofolate reductase inhibitor, standard folic acid may not be effective because the enzyme that converts folic acid to its active tetrahydrofolate form is blocked. In this situation, leucovorin (folinic acid) is given instead, as it bypasses the enzymatic block entirely. This is commonly known as "leucovorin rescue" and is a frequently tested concept.

In pregnancy, folic acid supplementation is recommended at 0.4 mg daily for all women of childbearing age to prevent neural tube defects. Women with a history of a prior pregnancy affected by a neural tube defect should receive the higher dose of 4 mg daily, starting at least one month before conception.

Dietary counseling is also part of long-term management. Folate-rich foods include leafy green vegetables, legumes, fortified cereals, and citrus fruits. However, folate is heat-labile and destroyed by prolonged cooking, which partly explains why dietary deficiency is common in populations with limited access to fresh produce.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with folic acid deficiency is confusing it with vitamin B12 deficiency. Both cause identical hematologic findings: macrocytic anemia, hypersegmented neutrophils, and elevated homocysteine. The vignette will almost always include one detail that separates them. If the patient has neurological symptoms (numbness, tingling, difficulty walking, loss of proprioception), the answer is B12 deficiency. If the patient is described as an alcoholic with poor dietary intake and no neurological findings, the answer is folate deficiency. The lab discriminator is methylmalonic acid: normal in folate deficiency, elevated in B12 deficiency.

The second major trap is the treatment question where a patient with megaloblastic anemia is started on folate alone without checking B12. The tested concept here is that folate corrects the anemia but masks ongoing B12-related neurological deterioration. If the question asks "what is the most important step before initiating treatment," the answer is checking a B12 level.

A third tested concept involves drug-induced folate deficiency. Methotrexate inhibits dihydrofolate reductase, trimethoprim weakly inhibits the same enzyme, and phenytoin impairs folate absorption. When the vignette includes one of these medications, you should recognize the mechanism and know that leucovorin (folinic acid), not standard folic acid, is the rescue agent for methotrexate toxicity.

Finally, watch for the pregnancy-related question. The tested concept is dosing: 0.4 mg daily for standard prophylaxis, 4 mg daily for women with a prior neural tube defect pregnancy. The timing matters too: supplementation must begin before conception because neural tube closure occurs within the first 28 days, often before a woman knows she is pregnant.

The core competency being tested across all these question types is the ability to distinguish folate deficiency from B12 deficiency using a combination of clinical presentation (presence or absence of neurological findings) and targeted laboratory interpretation (homocysteine versus methylmalonic acid), and to recognize the clinical danger of treating one without excluding the other.